南都讯 2月24日是农历丙午马年开工第一天，广东省高质量发展大会召开，聚焦制造业与服务业协同发 展这一主题，深化研讨在更高水平上推进高质量发展，更好带动广东"十五五"开好局、起好步。 "'新春第一会'，发出了坚定不移推动高质量发展的强音，为我们指明了前行方向。"广东医科大学校长 肖炜表示，学校将立足"智能医学与医学人工智能""海洋医药与热带医学"两大特色领域，统筹推进教 育、科技、人才一体化发展，全力服务广东生物医药产业升级与健康广东建设。 聚焦"医工融合、AI赋能"，培育产业急需的高素质人才。学校将"人工智能+"作为改革创新核心方向， 以AI医学院、华为医学人工智能现代产业学院等平台为载体，加快建设"医学人工智能概念验证中心与 中试基地"，打造服务于智能医学装备与医疗器械研发的CXO科技服务平台。通过推进联合学士学位培 养、微专业、特色创新班等模式改革，大力培养兼具医学知识与工程技术的复合型创新人才。我们正全 力推动海东校区建设，积极融入省高等教育"迎峰计划"，优化多校区资源协同机制，为生物医药与大健 康产业提供坚实人才支撑。 聚焦"国家所需、湾区所向"，打造高能级创新策源平台。学校紧密围绕国家海洋战略、生 ...

1月31日，厦门大学附属心血管病医院（简称"厦心医院"）TAVR^2S 2026国际峰会直播屏幕上，一场手术正在颠覆传统认知：手术台前，不见 穿着厚重铅衣的医护人员忙碌穿梭，取而代之的是一台医院自主研发的国产机器人；手术间外，院长王焱教授在控制台前轻握摇杆，操控机 械臂在跳动的心脏上完成了亚毫米级二尖瓣微创修复。 这场由厦心医院主办的峰会，不仅是国内首个聚焦二尖瓣、三尖瓣介入治疗的国际学术平台，更是中国结构性心脏病治疗创新实力的集中展 示。三天里，来自全球20余个国家和地区的顶尖心脏介入专家，通过十余台高难度手术直播及深度病例研讨、前沿主旨演讲，目睹了中国方 案从"追赶者"到"定义者"的蜕变。 技术突破 然而，十年前我国在该领域仍处于"跟跑"阶段。"国外完成首例相关手术大概8到10年后，我们才开展第一例。"中国科学院院士葛均波说，过 去十年，国产器械在主动脉瓣领域日趋成熟，在三尖瓣研发上已实现"国际领跑"，在二尖瓣领域也完成了从"跟跑"到"并跑"的跨越。 中国瓣膜介入从"跟跑"到"领跑" 此次演示的机器人辅助经导管二尖瓣修复术，正是这一跨越的缩影。这套由厦心参与自主研发的系统，融合高精度机械臂、智能控制、5G ...

Core Viewpoint - The Second Global Ophthalmology Conference 2026 will be held on June 11, 2026, in Beijing, focusing on the integration of medicine and engineering, technological innovation, and clinical value in the ophthalmology industry [1]. Event Overview - The conference will cover various fields including ophthalmic imaging, refractive and myopia treatment, innovative therapies, surgical techniques, and preclinical validation [1]. - The event will also open applications for the "2026 Global Ophthalmology Annual Awards" and invite teams to co-author the "Global Ophthalmology Innovation White Paper" [2]. Conference Highlights - The conference will feature the release of the "2026 Global Ophthalmology Innovation White Paper" and the awarding of the "Ophthalmology Innovation Series Awards" to establish industry benchmarks [7]. - There will be premium exhibition spaces for sponsors to engage with high-quality decision-makers, product demonstrations, and collaboration opportunities [7]. - An "Innovation Demo Hour" will allow selected innovative teams to present their projects in 5-10 minute high-density pitches, addressing investment and collaboration needs [14]. Thematic Focus Areas - **Next-Generation Ophthalmic Imaging and AI**: This section will explore the integration of imaging and algorithms, focusing on academic advancements and practical applications [11]. - **Refractive and Myopia**: This segment will address the largest commercial segment in China's ophthalmology industry, discussing refined surgical developments and comprehensive strategies for myopia prevention [13]. - **Surgical Innovations**: This part will showcase the next-generation technologies in ophthalmic surgery, including robotics and real-time imaging [13]. - **Device Development and Preclinical Validation**: This section will present the system of "industrial service chains" to assist R&D and innovation companies in resource matching [13]. Participant Demographics - The conference will attract a diverse audience, including academic teams with recent research outcomes, engineering teams with prototype products, and early-stage innovative companies [16].

Core Viewpoint - The rehabilitation medical industry in China is undergoing significant transformation driven by technological innovation and a focus on clinical needs, as evidenced by the experiences of young entrepreneurs like Wang Daoyu [1][10]. Group 1: Industry Challenges - The rehabilitation medical industry faced initial challenges such as weak supply and heavy reliance on imports, particularly for high-end rehabilitation robots, which were scarce and expensive [2]. - The core contradiction in the industry was the imbalance between patient rehabilitation needs and the insufficient supply of quality rehabilitation resources, especially products tailored to local clinical scenarios [2]. - The industry is characterized by long development cycles and high investment requirements, with product development taking over four years from research to market launch [4][5]. Group 2: Technological Innovation - The focus of technological innovation has shifted from complex structures to addressing clinical needs, emphasizing the importance of practical solutions for patients [6]. - Innovations include the application of eye-tracking technology for rehabilitation training and AI integration for dynamic adjustment of rehabilitation plans based on patient data [6]. - Full-stack self-research is identified as a key direction for technological innovation, aiming to reduce costs and enhance adaptability through proprietary technology [6]. Group 3: Industry Standards and Collaboration - The establishment of industry standards is crucial for the healthy development of the rehabilitation medical field, as early practitioners played a significant role in drafting relevant standards [7]. - Collaboration among industry, academia, and research institutions is essential for aligning technology development with clinical needs and accelerating the translation of technological achievements [7]. Group 4: Future Trends - The rehabilitation medical industry is expected to extend from institutional settings to home care, with a growing demand for practical home rehabilitation products [8]. - Achieving equal access to rehabilitation services across different regions is a key challenge, with the potential for "robot + IoT" models to provide remote rehabilitation services [9]. - The internationalization of Chinese rehabilitation medical technology is seen as viable, with industry alliances suggested as a means to enhance global competitiveness and market access [9]. Group 5: Entrepreneurial Insights - Patience and adherence to core values are emphasized as essential qualities for those entering the rehabilitation medical field, highlighting the importance of a supportive innovation ecosystem [10]. - The rich innovation resources and supportive policies in regions like Shanghai provide a solid foundation for the development of the rehabilitation medical industry [10].

Core Viewpoint - The strategic cooperation between Su Bei People's Hospital and Tuo Ren Holding Group marks a significant step towards enhancing healthcare innovation and integration in the Yangzhou region, contributing to the "Healthy Yangzhou" initiative [1][4]. Group 1: Strategic Cooperation - The partnership is described as a "marriage" between the two entities, emphasizing the importance of technological reform and medical-industrial integration in the local healthcare system [1]. - This collaboration aims to address the bottlenecks in the transformation of scientific achievements by integrating social resources and focusing on joint technological breakthroughs and talent cultivation [4]. Group 2: Goals and Objectives - The cooperation seeks to establish a "triangular" model of collaborative development that connects clinical needs, research innovation, and industrial transformation, aligning with national strategies for technological self-reliance [4]. - The initiative is expected to significantly enhance the hospital's research innovation efficiency and clinical service capabilities, propelling it towards becoming a high-level research hospital [4]. Group 3: Impact on Local Healthcare - The partnership is seen as a model for deep integration of production, education, research, and medicine, driven by actual clinical needs, which is highly supported by local health and technology authorities [5]. - It aims to accelerate the development of innovative medical products with high clinical value, improving healthcare services in Yangzhou and surrounding areas [5]. - The collaboration is anticipated to attract and cultivate high-end talent in the biomedicine sector, enhancing the overall competitiveness and cluster effect of Yangzhou in this industry [5].

Group 1 - The integration of AI in medicine and engineering is accelerating drug development, enhancing clinical precision, and driving innovation in the healthcare industry, providing stronger technological support for public health [1] - The newly launched AI drug development platform "AI Kongming" has shown significant improvements in candidate molecule hit rates and optimization efficiency, achieving several times to tens of times better results compared to traditional processes [2] - AI technologies are increasingly applied across various medical fields, including drug development, medical imaging, disease diagnosis, and health monitoring, demonstrating a broad impact on healthcare [3] Group 2 - Pharmaceutical companies like Shijiazhuang Pharmaceutical Group and Heng Rui Medicine are establishing AI research departments to expedite drug target discovery and clinical trial processes [4] - Platforms for innovation in medical-engineering integration are being developed, such as the Suzhou Industrial Park's platform for transforming innovative results and Haier's health technology innovation platform, aimed at breaking down barriers between data, disciplines, and institutions [5] - National policies are being introduced to promote the deep integration of new information technologies with the pharmaceutical industry, including guidelines that recognize AI-assisted diagnosis as an extension of pathological diagnosis [5]

Group 1 - The integration of AI in healthcare is accelerating drug development, enhancing clinical precision, and driving innovation in the medical industry, providing stronger technological support for public health [1][2] - The AI platform "AI Kongming" has been launched, offering free access to databases related to global health challenges, significantly improving candidate molecule hit rates and optimization efficiency by several times compared to traditional processes [1][2] - AI technologies are increasingly applied across various medical fields, including drug development, medical imaging, disease diagnosis, and health monitoring, showcasing their versatility and potential impact [2][3] Group 2 - Major pharmaceutical companies like Shijiazhuang Pharmaceutical Group and Hengrui Medicine are establishing AI research departments to accelerate drug target discovery and clinical trial processes [3][4] - The establishment of innovation platforms, such as the one in Suzhou Industrial Park, aims to facilitate the transformation of medical and engineering innovations, breaking down barriers between data, disciplines, and institutions [4][5] - National policies are being introduced to promote the integration of new information technologies with the pharmaceutical industry, enhancing the application of AI in clinical settings [4][5]

Core Insights - The "Spring Rain Action - Medical Device Clinical Research Results Transformation Promotion Conference" was held in Jinan, focusing on high-quality development paths for the medical device industry [1] - The establishment of the Shandong Medical Device Review and Inspection Center marks a significant advancement in the province's medical device review and inspection system, providing robust support for industry innovation [1] - The conference introduced a series of forward-looking policy measures aimed at promoting the high-quality development of the pharmaceutical and medical device industry in Shandong [1] Group 1 - The conference featured the unveiling of ten innovative results selected by the "Spring Rain Action," with five medical institutions and five quality enterprises signing strategic cooperation agreements for clinical research results transformation [2] - Experts from the National Medical Products Administration elaborated on the policy implications and implementation paths of the "Spring Rain Action," presenting a comprehensive policy support system covering the entire lifecycle from research and development to production [2] - The event fostered in-depth exchanges among participants, creating a strong consensus within the industry and laying the groundwork for future collaborations [2] Group 2 - The conference established a collaborative innovation system integrating government, medical institutions, industry, academia, and research, providing systematic support for the high-quality development of the medical device industry [3] - The ongoing deepening of the "Spring Rain Action" and the effectiveness of the Shandong Medical Device Review and Inspection Center are accelerating the formation of a closed-loop integration of medical and industrial collaboration [3] - This initiative aims to contribute significantly to the construction of a health-oriented China and enhance the overall health level of the population [3]

Core Viewpoint - The integration of medical and engineering fields is becoming a key driver for breakthroughs in high-end medical equipment and biopharmaceutical innovation, particularly in Zhuhai, which is positioned as a strategic hub in the Guangdong-Hong Kong-Macao Greater Bay Area [2]. Event Details - The "Medical-Engineering Integration Annual Conference 2025" will be held from December 26 to 28, 2025, in Zhuhai, Guangdong, aiming to promote high-quality development in the medical-engineering integration sector [2]. - The conference theme is "Jointly Inviting the Bay Area: Medical-Engineering Integration to Inspire the Future," focusing on creating a resource platform for collaboration among government, associations, hospitals, universities, research institutions, investment entities, and enterprises [2]. Organizing Institutions - The conference is guided by the China Medical and Health Culture Association and organized by Beijing Institute of Technology (Zhuhai), Zhuhai Health Bureau, and the Medical-Engineering Integration Branch of the China Medical and Health Culture Association [3]. Conference Highlights - The event will feature top scholars and industry leaders sharing insights on cutting-edge research and industry trends, fostering a collaborative ecosystem for project signing and talent introduction [60]. - A dedicated Zhuhai Medical-Engineering Integration Liaison Office will be established to provide ongoing support and services, including policy consultation and funding connections [60]. Main Content - The agenda includes leadership speeches, high-quality thematic forums, academic dialogues, and an award ceremony for outstanding orthopedic innovation projects [61]. - Resource matching sessions will be organized, including project roadshows and expert evaluations, along with site visits to local leading enterprises [61]. - Policy and service promotion will cover key industry policies in biomedicine, high-end medical equipment, and artificial intelligence [61].

Core Viewpoint - The article discusses the significant advancement in gastrointestinal endoscopy technology with the introduction of a domestic high-definition endoscope system combined with AI-assisted diagnostic capabilities in Xinjiang, China. This innovation aims to enhance the accuracy and efficiency of gastrointestinal disease screening and treatment in county-level medical settings, reducing the need for patients to travel to larger hospitals for care [1]. Part 1: Clinical Demand Discovery - The emergence of the AI-assisted gastrointestinal endoscopy system is driven by unmet clinical needs, particularly the challenge of early detection of small lesions in gastrointestinal cancer patients, which often leads to late-stage diagnoses [3][4]. - The system enhances lesion recognition, operational standardization, and diagnostic reliability through a collaborative approach involving doctors, equipment, and AI [5]. Part 2: Technical Solution Selection - Various technical paths were considered for the AI-assisted gastrointestinal endoscopy system, including software enhancements to existing equipment, hardware upgrades for improved imaging, and a combination of both [6][7]. - Path A focuses on adding AI capabilities to existing endoscope systems, exemplified by the GI Genius system, which has shown a 14.4% increase in adenoma detection rates [8]. - Path B involves upgrading hardware for better imaging quality, while Path C emphasizes a gradual approach starting with quality control before expanding to lesion detection [10][11]. Part 3: Cross-Disciplinary Team Collaboration - The development phase involves a collaborative ecosystem where algorithm engineers, hardware engineers, and clinical doctors work together to refine the AI system based on real-world clinical practices [14]. - Iterative prototyping and preclinical validation are crucial, with multiple stages of testing to ensure safety and effectiveness before clinical trials [15][16]. Part 4: Clinical Trials and Regulatory Approval - Clinical trials are essential for validating the safety and effectiveness of the AI-assisted endoscopy system, with early studies indicating significant improvements in adenoma detection rates [20][21]. - Regulatory bodies like the FDA and NMPA play a critical role in the approval process, focusing on the system's effectiveness, safety, and compatibility with existing medical devices [23][24]. Part 5: Productization and Clinical Application - After regulatory approval, the AI endoscopy product enters the commercialization phase, requiring adaptation to various hospital systems and ensuring compliance with medical device standards [30]. - Key players in this phase include manufacturing, marketing, and clinical support teams, with a focus on demonstrating clinical efficacy to encourage adoption [31]. Challenges and Key Factors - The commercialization process faces challenges such as high initial costs, skepticism from experienced doctors, and the need for standardized protocols to ensure consistent performance across different products [34][35]. - Long-term success in the market will depend on continuous innovation, collaboration within the industry, and the ability to demonstrate tangible clinical benefits to both doctors and patients [36].